Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Thrombocytopenia 1Purpura, Thrombocytopenic, Idiopathic 1Purpura, Thrombocytopenic 1

Interventions

emicizumab 4voxelotor 1romiplostim 1recombinant FVIIa 1olaparib 1maltodextrin 1lusutrombopag 1luspatercept 1ibrutinib 1fludarabine phosphate 1continuous erythropoietin receptor activator 1betrixaban 1anti-inhibitor coagulant complex 1Rituximab 1Pharmacogenomic Testing 1Glutamine 1Factor VIII 1Enoxaparin 1Cyclophosphamide 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × romiplostim × Classical hematology × Clear all
NCT01444417 2017-02-09

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Amgen

Phase 3 Completed
62 enrolled 16 charts 1 FDA
Classical hematology

Purpura, Thrombocytopenic, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡